TY - JOUR
T1 - Japanese guideline for adult asthma
AU - Ohta, Ken
AU - Yamaguchi, Masao
AU - Akiyama, Kazuo
AU - Adachi, Mitsuru
AU - Ichinose, Masakazu
AU - Takahashi, Kiyoshi
AU - Nishimuta, Toshiyuki
AU - Morikawa, Akihiro
AU - Nishima, Sankei
PY - 2011
Y1 - 2011
N2 - Adult bronchial asthma (hereinafter, asthma) is characterized by chronic airway inflammation, reversible airway narrowing, and airway hyperresponsiveness. Long-standing asthma induces airway remodeling to cause an intractable asthma. The number of patients with asthma has increased, while the number of patients who die from asthma has decreased (1.7 per 100,000 patients in 2009). The aim of asthma treatment is to enable patients with asthma to lead a healthy life without any symptoms. A partnership between physicians and patients is indispensable for appropriate treatment. Long-term management with agents and elimination of causes and risk factors are fundamental to asthma treatment. Four steps in pharmacotherapy differentiate mild to intensive treatments; each step includes an appropriate daily dose of an inhaled corticosteroid (ICS), varying from low to high doses. Long-acting β2 agonists (LABA), leukotriene receptor antagonists, and theophylline sustainedrelease preparation are recommended as concomitant drugs, while anti-IgE antibody therapy is a new choice for the most severe and persistent asthma. Inhaled β2 agonists, aminophylline, corticosteroids, adrenaline, oxygen therapy, etc., are used as needed against acute exacerbations. Allergic rhinitis, chronic obstructive pulmonary disease (COPD), aspirin induced asthma, pregnancy, and cough variant asthma are also important factors that need to be considered.
AB - Adult bronchial asthma (hereinafter, asthma) is characterized by chronic airway inflammation, reversible airway narrowing, and airway hyperresponsiveness. Long-standing asthma induces airway remodeling to cause an intractable asthma. The number of patients with asthma has increased, while the number of patients who die from asthma has decreased (1.7 per 100,000 patients in 2009). The aim of asthma treatment is to enable patients with asthma to lead a healthy life without any symptoms. A partnership between physicians and patients is indispensable for appropriate treatment. Long-term management with agents and elimination of causes and risk factors are fundamental to asthma treatment. Four steps in pharmacotherapy differentiate mild to intensive treatments; each step includes an appropriate daily dose of an inhaled corticosteroid (ICS), varying from low to high doses. Long-acting β2 agonists (LABA), leukotriene receptor antagonists, and theophylline sustainedrelease preparation are recommended as concomitant drugs, while anti-IgE antibody therapy is a new choice for the most severe and persistent asthma. Inhaled β2 agonists, aminophylline, corticosteroids, adrenaline, oxygen therapy, etc., are used as needed against acute exacerbations. Allergic rhinitis, chronic obstructive pulmonary disease (COPD), aspirin induced asthma, pregnancy, and cough variant asthma are also important factors that need to be considered.
KW - Acute exacerbation
KW - Control of asthma
KW - Epidemiology of asthma
KW - Patient education
KW - Treatment step
UR - http://www.scopus.com/inward/record.url?scp=79959613229&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79959613229&partnerID=8YFLogxK
U2 - 10.2332/allergolint.11-RAI-0327
DO - 10.2332/allergolint.11-RAI-0327
M3 - Review article
C2 - 21636963
AN - SCOPUS:79959613229
VL - 60
SP - 115
EP - 145
JO - Allergology International
JF - Allergology International
SN - 1323-8930
IS - 2
ER -